JP2017519765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519765A5 JP2017519765A5 JP2016573772A JP2016573772A JP2017519765A5 JP 2017519765 A5 JP2017519765 A5 JP 2017519765A5 JP 2016573772 A JP2016573772 A JP 2016573772A JP 2016573772 A JP2016573772 A JP 2016573772A JP 2017519765 A5 JP2017519765 A5 JP 2017519765A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 72
- 239000000203 mixture Substances 0.000 claims 36
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 24
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 24
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 24
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 24
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 16
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 16
- 230000000694 effects Effects 0.000 claims 11
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 6
- 210000001124 body fluid Anatomy 0.000 claims 6
- 239000010839 body fluid Substances 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 4
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 4
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 4
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 4
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 4
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 4
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 4
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 4
- 208000020446 Cardiac disease Diseases 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 230000010247 heart contraction Effects 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 claims 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 claims 2
- 230000004217 heart function Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims 1
- 102000013394 Troponin I Human genes 0.000 claims 1
- 108010065729 Troponin I Proteins 0.000 claims 1
- 102000004987 Troponin T Human genes 0.000 claims 1
- 108090001108 Troponin T Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 108091022862 fatty acid binding Proteins 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001452 natriuretic effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015093P | 2014-06-20 | 2014-06-20 | |
| US62/015,093 | 2014-06-20 | ||
| PCT/US2015/036790 WO2015196142A1 (en) | 2014-06-20 | 2015-06-19 | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020105424A Division JP2020147609A (ja) | 2014-06-20 | 2020-06-18 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519765A JP2017519765A (ja) | 2017-07-20 |
| JP2017519765A5 true JP2017519765A5 (enExample) | 2018-07-26 |
| JP6910800B2 JP6910800B2 (ja) | 2021-07-28 |
Family
ID=53724442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573772A Active JP6910800B2 (ja) | 2014-06-20 | 2015-06-19 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
| JP2020105424A Pending JP2020147609A (ja) | 2014-06-20 | 2020-06-18 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020105424A Pending JP2020147609A (ja) | 2014-06-20 | 2020-06-18 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170137505A1 (enExample) |
| EP (1) | EP3157952B1 (enExample) |
| JP (2) | JP6910800B2 (enExample) |
| WO (1) | WO2015196142A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100689A1 (en) | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| CA2956256A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| JP7138567B2 (ja) | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
| JP2020503842A (ja) * | 2016-10-12 | 2020-02-06 | ヤンセン バイオテツク，インコーポレーテツド | Ｇｄｆ１５様生物活性の調節因子をスクリーニングするための方法 |
| KR102715542B1 (ko) | 2018-08-20 | 2024-10-08 | 화이자 인코포레이티드 | 항-gdf15 항체, 조성물 및 사용 방법 |
| JP2024541933A (ja) | 2021-11-02 | 2024-11-13 | ファイザー・インク | 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5733254A (en) | 1987-10-15 | 1998-03-31 | Cypress Bioscience, Inc. | Method for treating patients suffering from immune thrombocytopenic purpura |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| AU2002257420A1 (en) | 2001-05-01 | 2002-11-11 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7157235B2 (en) * | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| ES2555956T3 (es) * | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| CA2660691C (en) * | 2006-08-04 | 2020-01-14 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| WO2009021293A1 (en) * | 2007-08-16 | 2009-02-19 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| JP2011502106A (ja) * | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法 |
| TR201802772T4 (tr) * | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2014100689A1 (en) * | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
-
2015
- 2015-06-19 EP EP15742142.1A patent/EP3157952B1/en active Active
- 2015-06-19 US US15/320,094 patent/US20170137505A1/en not_active Abandoned
- 2015-06-19 WO PCT/US2015/036790 patent/WO2015196142A1/en not_active Ceased
- 2015-06-19 JP JP2016573772A patent/JP6910800B2/ja active Active
-
2018
- 2018-11-01 US US16/177,792 patent/US20190292251A1/en not_active Abandoned
-
2020
- 2020-06-18 JP JP2020105424A patent/JP2020147609A/ja active Pending
-
2022
- 2022-02-02 US US17/649,732 patent/US20220403015A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519765A5 (enExample) | ||
| WO2009086539A4 (en) | Treatment and prophylaxis of amyloidosis | |
| JP2018506277A5 (enExample) | ||
| JP2020513786A5 (enExample) | ||
| JP2012513193A5 (enExample) | ||
| JP2014523902A5 (enExample) | ||
| WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
| JP2011511780A5 (enExample) | ||
| CA2786479A1 (en) | Methods for treating pancreatic cancer | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| RU2011144166A (ru) | Способы применения антител к il-22 человека | |
| JP2016063812A5 (enExample) | ||
| JP2007522096A5 (enExample) | ||
| WO2009103105A3 (en) | Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders | |
| SA517390230B1 (ar) | Rgma بــروتــيــن رابــط لــ واســـتــخـدامـــه | |
| SI2833907T1 (en) | COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA | |
| RU2003126168A (ru) | Терапевтические связывающие молекулы | |
| JP2019503686A5 (enExample) | ||
| JP2016525502A5 (enExample) | ||
| JP2010504336A5 (enExample) | ||
| JP2017519764A5 (enExample) | ||
| JP2019529371A5 (enExample) | ||
| EP4491268A3 (en) | Fc binding proteins with cysteine in the c-terminal helical region | |
| JP2020511502A5 (enExample) | ||
| JP2016536357A5 (enExample) |